ArticleAnnals of translational medicine2021
Distinctive genomic characteristics in
Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 37 citations in OpenAlex.
- Tumor-Type-Specific Tumor Mutational Burden Cutoffs for Improved Immune Checkpoint Inhibitor Outcome Prediction: Large-Scale Analysis with Real-World Targeted Next-Generation Sequencing Data.Cancer research and treatment · 2026Article
- Navigating Immunotherapy in a Kidney Transplant Recipient: A Case Report of POLE-Mutated Jejunal Adenocarcinoma.Cureus · 2026Article
- Innovative immunotherapy approaches: harnessing synergy of dual checkpoint blockade in oncology.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy.Cancer cell · 2025Review
- Beyond proofreading: POLD1 mutations as dynamic orchestrators of genomic instability and immune evasion in cancer.Frontiers in immunology · 2025Review
- Case Report: Metastatic small bowel adenocarcinoma with DNA mismatch repair deficiency in an organ transplant recipient treated with anti-PD-1 immunotherapy.Frontiers in oncology · 2025Article
- DNA polymerase POLD1 promotes proliferation and metastasis of bladder cancer by stabilizing MYC.Nature communications · 2023Article
- Candidate variants in DNA replication and repair genes in early-onset renal cell carcinoma patients referred for germline testing.BMC genomics · 2023Article
- POLD1 as a Prognostic Biomarker Correlated with Cell Proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma.International journal of molecular sciences · 2023Article
- Prospects of POLD1 in Human Cancers: A Review.Cancers · 2023Review
- Challenges and exploration for immunotherapies targeting cold colorectal cancer.World journal of gastrointestinal oncology · 2023Review
- Altered immunoexpression of DNA polymerase delta 1 catalytic subunit (POLD1) in colorectal cancer.Contemporary oncology (Poznan, Poland) · 2023Article
- Identification of genes and cellular response factors related to immunotherapy response in mismatch repair-proficient colorectal cancer: a bioinformatics analysis.Journal of gastrointestinal oncology · 2022Article
- POLE/POLD1 mutation and tumor immunotherapy.Journal of experimental & clinical cancer research : CR · 2022Review
- Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity.Nature genetics · 2022Article
- Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboringJournal for immunotherapy of cancer · 2022Article
- Preparation of Duplex Sequencing Libraries for Archival Paraffin-Embedded Tissue Samples Using Single-Strand-Specific Nuclease P1.International journal of molecular sciences · 2022Article
- Article
- HROP68: A rare case of medullary pancreatic cancer-characterization and chemosensitivity of the first patient-derived cell line.Frontiers in oncology · 2022Article
- Immune Checkpoint Inhibitors in Tumors Harboring Homologous Recombination Deficiency: Challenges in Attaining Efficacy.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMutations in
methodsGenomic data of 21,074 patients with 23 cancer types were retrieved from Burning Rock variant database (BR VarDB). The prevalence and spectra of
resultsBR VarDB samples displayed a similar mutational prevalence of
conclusionsWe delineated distinctive genomic characteristics in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.